MageA1-TCR gene therapy - MediGene

Drug Profile

MageA1-TCR gene therapy - MediGene

Latest Information Update: 17 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MediGene AG
  • Class Immunotherapies
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 17 Mar 2017 MediGene plans a phase I/II trial for an undisclosed indication in the second half of 2018 (MediGene pipeline, March 2017)
  • 17 Mar 2017 MediGene plans a clinical trial for an undisclosed indication in the second half of 2017 (MediGene pipeline, March 2017)
  • 16 Nov 2016 MediGene, Max Delbruck Centre plan a phase I trial for Multiple myeloma (MediGene website, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top